Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Clinical trial NCT06441747 · RECRUITING
Trial details
- NCT number
- NCT06441747
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-23
- Primary completion
- 2026-08-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.